Can Artificial Intelligence Revolutionize Drug Discovery?
Finding new drugs is a major challenge in the face of emerging infectious diseases and persistent pathologies. Traditional methods, which are lengthy and costly, struggle to quickly meet global needs. Artificial intelligence offers a promising solution by accelerating and optimizing each step of this complex process.
Artificial intelligence uses advanced algorithms to analyze vast amounts of biological and chemical data. It enables faster identification of potential therapeutic targets and selection of molecules capable of inhibiting them. Through techniques such as machine learning and neural networks, researchers can predict the efficacy and safety of compounds even before testing them in the lab. These tools reduce errors and costs while increasing the precision of results.
One of the major strengths of artificial intelligence is its ability to repurpose existing drugs for new uses. By analyzing massive databases, it reveals unexpected links between molecules and diseases, paving the way for innovative treatments without starting from scratch. For example, drugs initially developed for arthritis have been identified as potentially effective against severe viral infections.
Algorithms play a key role in simulating interactions between drugs and their targets. They assess essential properties such as toxicity, stability, and the ability to reach the affected area in the body. These analyses, completed in just a few hours, would have taken years using traditional methods. Additionally, artificial intelligence facilitates the design of custom molecules tailored to specific diseases or even individual patients, marking a step forward toward more personalized medicine.
In clinical trials, artificial intelligence optimizes patient recruitment and analyzes data in real time. It allows for faster protocol adjustments and identification of treatment responses with increased precision. Platforms like IBM Watson use these technologies to cross-reference medical and genetic information, thereby improving the efficiency of tests.
However, challenges remain. The quality and quantity of available data are crucial for ensuring reliable predictions. Models must be transparent and understandable to gain the trust of researchers and regulators. Ethical issues, such as patient data protection, also require special attention.
Despite these obstacles, progress is tangible. Pharmaceutical companies are already integrating these technologies to develop treatments for cancer, rare diseases, and resistant infections. The results show a significant reduction in time and costs, while increasing the chances of success.
Artificial intelligence is thus transforming drug discovery, making possible what seemed out of reach just a short time ago. Its potential to improve global health is immense, provided that innovation and collaboration continue among scientists, industry, and regulators.
Sources and Credits
Source Study
DOI: https://doi.org/10.1186/s43094-026-00954-3
Title: Navigation of drug discovery via artificial intelligence
Journal: Future Journal of Pharmaceutical Sciences
Publisher: Springer Science and Business Media LLC
Authors: Saurav Kumar Mishra; Jeba Praba J; Hamadou Mamoudou; Akansha Subba; John J. Georrge